Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects

Wenlu Zou,1– 3,&ast; Jie Lu,4,&ast; Yan Hao5 1Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, 250021, People’s Republic of China; 2Department of Infectious Disease; 3Department of Clinical Laboratory, Sha...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Zou W, Lu J, Hao Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	immunomyocarditis immune checkpoint inhibitors anti-pd-1/pd-l1 cancer Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/e9b4104019a14d928232038017a3be94
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e9b4104019a14d928232038017a3be94
record_format	dspace
spelling	oai:doaj.org-article:e9b4104019a14d928232038017a3be942021-12-02T16:15:13ZMyocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects1178-7031https://doaj.org/article/e9b4104019a14d928232038017a3be942021-07-01T00:00:00Zhttps://www.dovepress.com/myocarditis-induced-by-immune-checkpoint-inhibitors-mechanisms-and-the-peer-reviewed-fulltext-article-JIRhttps://doaj.org/toc/1178-7031Wenlu Zou,1– 3,&ast; Jie Lu,4,&ast; Yan Hao5 1Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, 250021, People’s Republic of China; 2Department of Infectious Disease; 3Department of Clinical Laboratory, Shandong University Qilu Hospital, Jinan, Shandong Province, 250012, People’s Republic of China; 4Department of Neurosurgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Neurosurgery, Jinan, 250117, Shandong Province, People’s Republic of China; 5Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong Province, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Yan Hao Email haoyan02_09@sina.comAbstract: Under physiological conditions, immune checkpoint molecules downregulate the activation and effector function of myocardial antigen-reactive T cells through an immunosuppressive pathway, thus enabling myocardial T cells to maintain immune homeostasis under the action of central and peripheral tolerance mechanisms. The PD-1/PD-L1 signalling pathway is particularly important for limiting the ability of T cells to attack the heart. Immune checkpoint inhibitors (ICIs) specifically block this PD-1/PD-L1-mediated restriction of T cell activation and other immunosuppressive pathways by targeting immune checkpoints. In recent years, with the wide use of ICIs in cancer treatment, even though the incidence of immunomyocarditis is low, it has attracted increasing attention because of its complex clinical symptoms, rapid progression of disease and high mortality rates. The pathogenesis, genetic susceptibility factors and predictive biomarkers of immunomyocarditis still need to be understood, and multidisciplinary cooperation in the clinical treatment of this complication is necessary.Keywords: immunomyocarditis, immune checkpoint inhibitors, anti-PD-1/PD-L1, cancerZou WLu JHao YDove Medical Pressarticleimmunomyocarditisimmune checkpoint inhibitorsanti-pd-1/pd-l1cancerPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 3077-3088 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	immunomyocarditis immune checkpoint inhibitors anti-pd-1/pd-l1 cancer Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	immunomyocarditis immune checkpoint inhibitors anti-pd-1/pd-l1 cancer Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Zou W Lu J Hao Y Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
description	Wenlu Zou,1– 3,&ast; Jie Lu,4,&ast; Yan Hao5 1Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, 250021, People’s Republic of China; 2Department of Infectious Disease; 3Department of Clinical Laboratory, Shandong University Qilu Hospital, Jinan, Shandong Province, 250012, People’s Republic of China; 4Department of Neurosurgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Neurosurgery, Jinan, 250117, Shandong Province, People’s Republic of China; 5Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong Province, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Yan Hao Email haoyan02_09@sina.comAbstract: Under physiological conditions, immune checkpoint molecules downregulate the activation and effector function of myocardial antigen-reactive T cells through an immunosuppressive pathway, thus enabling myocardial T cells to maintain immune homeostasis under the action of central and peripheral tolerance mechanisms. The PD-1/PD-L1 signalling pathway is particularly important for limiting the ability of T cells to attack the heart. Immune checkpoint inhibitors (ICIs) specifically block this PD-1/PD-L1-mediated restriction of T cell activation and other immunosuppressive pathways by targeting immune checkpoints. In recent years, with the wide use of ICIs in cancer treatment, even though the incidence of immunomyocarditis is low, it has attracted increasing attention because of its complex clinical symptoms, rapid progression of disease and high mortality rates. The pathogenesis, genetic susceptibility factors and predictive biomarkers of immunomyocarditis still need to be understood, and multidisciplinary cooperation in the clinical treatment of this complication is necessary.Keywords: immunomyocarditis, immune checkpoint inhibitors, anti-PD-1/PD-L1, cancer
format	article
author	Zou W Lu J Hao Y
author_facet	Zou W Lu J Hao Y
author_sort	Zou W
title	Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
title_short	Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
title_full	Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
title_fullStr	Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
title_full_unstemmed	Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
title_sort	myocarditis induced by immune checkpoint inhibitors: mechanisms and therapeutic prospects
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/e9b4104019a14d928232038017a3be94
work_keys_str_mv	AT zouw myocarditisinducedbyimmunecheckpointinhibitorsmechanismsandtherapeuticprospects AT luj myocarditisinducedbyimmunecheckpointinhibitorsmechanismsandtherapeuticprospects AT haoy myocarditisinducedbyimmunecheckpointinhibitorsmechanismsandtherapeuticprospects
_version_	1718384325346459648

Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects

Ejemplares similares